Comparative Pharmacology
Head-to-head clinical analysis: HC 1 versus PSORCON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HC 1 versus PSORCON.
HC #1 vs PSORCON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Unknown
Psorcon (diflorasone diacetate) is a corticosteroid that acts by inducing phospholipase A2 inhibitory proteins, collectively called lipocortins. It inhibits the release of arachidonic acid, thereby decreasing the formation of prostaglandins and leukotrienes, leading to anti-inflammatory, antipruritic, and vasoconstrictive effects.
Hydrocortisone: 100-200 mg IV as initial dose, then 50-100 mg IV every 6 hours, or 0.18 mg/kg/h IV continuous infusion.
Apply a thin layer to affected skin twice daily. For scalp conditions, use lotion or shampoo as directed.
None Documented
None Documented
2–4 hours (terminal); prolonged in renal impairment.
Terminal elimination half-life is approximately 2 hours (range 1.5–3 hours) after topical application; clinical significance: short half-life allows twice-daily dosing.
Renal: 90% as unchanged drug; fecal: 10%.
Primarily renal (about 70% as unchanged drug and metabolites); biliary/fecal elimination of approximately 30%.
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid